|
|
||||||||



* Dermatology and
Experimental Transplantation and Immunology Branches, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892; and
Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI 48109
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Attachment of leukocytes to the blood vessel wall occurs initially via
transient (rolling) interactions mediated by selectins
(3). For instance, E-selectin, is up-regulated by inflamed
dermal endothelial cells and is thought to mediate the binding of a
subset of skin-homing memory T cells
(mTC)2 that express specific
carbohydrate-based E-selectin ligands located on a protein backbone of
P-selectin glycoprotein ligand 1 (4). Enzymes such
as
(1, 3)fucosyltransferase VII (FT7) are essential for the T cells
to decorate P-selectin glycoprotein ligand 1 with appropriate
E-selectin carbohydrate ligands (5, 6). The
E-selectin-binding epitopes have been termed cutaneous
lymphocyte-associated Ag (CLA) when detected by the HECA452 mAb
(7).
In the multistep model of leukocyte recruitment, T cell rolling is followed by chemokine-triggered, integrin-mediated firm adhesion (3). Several chemokines, including CXCL12 (stromal cell-derived factor-1), CCL21 (secondary lymphoid-tissue chemokine), CCL17 (thymus and activation-regulated chemokine), and CCL20 (liver and activation-regulated chemokine) have been shown to induce arrest of T cells to recombinant adhesion molecules in vitro (8, 9, 10).
Chemokines trigger changes in both LFA-1 (CD11aCD18 integrin) affinity and avidity, both of which may contribute to integrin-mediated firm arrest (11). Notably, inhibitors of integrin lateral mobility (i.e., calpeptin) block adhesion of lymphocytes to ICAM-1 at low, but not high, site densities (11). Also, chemokine receptors on T cells polarize in response to ligand and cluster at the leading (migrating) edge of the cell (12), although neutrophils do not show this response and may redistribute intracellular molecules such as the AKT protein kinase to the migrating edge of the cell (13).
CCR6 is involved in dendritic cell trafficking to lymphoid organs
(14, 15) and is also exclusively expressed by memory, but
not naive, T cell subsets (16). CCR6 may be involved in
skin homing as suggested by its up-regulation in the inflammatory skin
condition known as psoriasis (17) and by apparent
skin-homing defects in T cells from CCR6-null mice (15).
CCL20, a ligand for CCR6, is strongly up-regulated in both HUVEC and
human dermal microvascular endothelial cells (HDMEC) by inflammatory
cytokines such as TNF-
(10, 18). Our previous study
showed that inhibition of CCR6 effectively prevented the arrest of mTC
on TNF-
activated HDMEC under shear stress, suggesting that CCR6 was
required for efficient arrest of a arrest of a subset of mTC on acutely
inflamed vascular endothelium (10).
Herein, we transduce Jurkat (JK) T cells with a retroviral vector that
expressed a fusion protein consisting of CCR6 linked to enhanced green
fluorescent protein (EGFP). Using these transduced JK cells, we
demonstrate that the expression of CCR6 results in a 2- to 3-fold
increase in T cell adhesion to activated endothelial cells. Moreover,
we take advantage of the EGFP-tagged CCR6 protein in order to follow
the reorganization of CCR6 following arrest in real time and in order
to detect CCR6s localization with respect to
2
integrin. We show that with respect to chemokine receptors, CCR6 alone
is sufficient to increase arrest of JK cells on activated microvascular
endothelial cells and suggest that CCR6-mediated clustering of selected
integrins may play a role in strengthening adhesion of T cells to
endothelial cells.
| Materials and Methods |
|---|
|
|
|---|
Anti-human
1 integrin mAb (33B6)
(19) was a gift of Dr. S. I. Simon (University of
California, Davis, CA). Anti-human CD11a mAb (R3.1) (20)
was provided by Dr. R. Rothlein (Boehringer-Ingelheim, Ridgefield, CT).
All other anti-human mAb were purchased from BD PharMingen (San
Diego, CA) unless otherwise indicated. Recombinant human chemokines
were purchased from PeproTech (Rocky Hill, NJ). Human E-selectin/Ig
chimera (21) was provided by Dr. S. Rosen (University of
California, San Francisco, CA). Soluble human ICAM-1 and a
nonfunction-blocking mouse anti-human ICAM-1 mAb (P79, mouse IgG1)
were gifts of Dr. T. Kishimoto (Boehringer-Ingelheim). FT7-transfected
JK T cell line (JKFT7) (22) and subsequent transduced
lines were cultured in complete RPMI 1640 medium with 10% FCS (cRPMI).
Recombinant human VCAM-1/Ig chimera was purchased from R&D Systems
(Minneapolis, MN). HDMEC were obtained from the Emory University School
of Medicine Dermatology Department cell culture facility (Atlanta, GA),
cultured as described (23), and used in passages
36.
Construction of CCR6-EGFP fusion vector
Using a CCR6 cDNA clone provided by Dr. J. Farber, (National Institute of Allergy and Infectious Diseases, Bethesda, MD), we PCR-amplified the CCR6 open reading frame using the forward primer (5'-AAA CTC GAG ATG AGC GGG GAA TCA ATG A-3') and the reverse primer (5'-AGC AAG CTT CAT AGT GAA GGA CGA CGC AT-3'). This amplified CCR6 fragment was digested with XhoI and HindIII and inserted into retroviral vector pLEGFP-N1 at complementary sites (Clontech, Palo Alto, CA). Thus, after construction, the PCCR6-LEGFP-N1 vector contained an open reading frame for EGFP that was located at 57 bp downstream of the 3' end of the CCR6 cDNA.
Transduction and selection of transduced cells
GP-293 packaging cells (Clontech) were cultured in a 150-mm culture dish 1 day after transfection using FuGene6 reagent (Roche Molecular Biochemicals, Indianapolis, IN). After cells reached 5070% confluency, FuGene6 (60 µl) was added to 1.5 ml serum-free medium and gently mixed with 10 µg of pCCR6-EGFP (or pLEGFP) together with 10 µg pVSVG viral coat protein vector. After incubation at 20°C for 30 min, this mixture was added to the GP-293 packaging cells and incubated at 37°C for 3 days.
Virus was harvested from cultured supernatants at 48 and 72 h after transfection, and filtered through a 0.45-µm polyvinylidene difluoride filter (Millipore, Bedford, MA). The viral supernatant was concentrated by repeated centrifugation at 80,000 x g for 2 h at 4°C. The resulting pellet was resuspended in 3 ml of fresh RPMI 1640 medium with polybrene (8 µg/ml; Sigma-Aldrich, St. Louis, MO) and then added 0.5 ml/well to JKFT7 cells that had been subcultured into six-well culture dishes coated with fibronectin. Seven days after transduction, EGFP-positive JKFT7 cells were initially isolated by FACS using a water-cooled argon-ion laser emitting at 488 nm for excitation and a 530/30-nm narrow bandpass filter for emission detection (FACSVantage SE; BD Biosciences, Mountain View, CA). One week later, further purification of CCR6-EGFP-positive cells was carried out using FITC-labeled anti-CCR6 mAb (R&D Systems) followed by anti-FITC-coated magnetic beads and positive magnetic selection (Miltenyi Biotec, Auburn, CA).
Flow cytometric analysis
Expression of chemokine receptors on JKFT7 cells was confirmed by staining cells with PE-labeled CCR6-specific or PE-labeled anti-CXCR4 mAb (both from BD PharMingen) in PBS with 1% BSA. After incubation at 4°C for 30 min, cells were washed twice with PBS with 0.1% BSA and analyzed using a FACScan (BD Biosciences) flow cytometer. Anti-integrin Abs were used as unlabeled primary mAb (anti-CD29) followed by labeling with a PE-conjugated secondary Ab or were used as described above as PE-conjugated primary mAbs (anti-CD11a, CD18, and CD49d).
Chemotaxis assay
Microchemotaxis chambers (ChemoTx no. 101-8, 8-µm pore size; NeuroProbe, Gaithersburg, MD) were used for chemotaxis assays as described (24). cRPMI (29 µl) containing chemokines were loaded in the lower wells. JKFT7 cells transduced with EGFP alone (JKFT7-EGFP) or CCR6-EGFP (JKFT7-CCR6) were stained with calcein-AM for 1530 min at 37°C (Molecular Probes, Eugene, OR) followed by washing with PBS and resuspension in the cRPMI. Cells in 25 µl of cRPMI were applied to top of the filter in triplicate and allowed to incubate for 3 h at 37°C. The contents of the lower wells were then carefully pooled together, brought to a final volume of 300 µl and then counted on a flow cytometer for 90 s.
In vitro flow assays
E-selectin/human IgG (100 µl at 1 µg/ml) and an anti-human ICAM-1 mAb (p79, 1 µg/ml) were applied overnight to nontreated plastic culture dishes in TBS as described (10). After a brief rinse with TBS, chemokines (40 µl, 10 µg/ml) in TBS were applied for 1.5 h at room temperature. After rinsing twice in TBS, soluble ICAM-1 (50 µl, 10 µg/ml) in PBS with 1% BSA was applied to the plate for 1.5 h at room temperature. Both JKFT7 cells which expressed EGFP only or expressed CCR6-EGFP were collected and resuspended at 0.5 x 106/ml in cRPMI in 12-ml syringe, which was fixed to a precision syringe pump (Harvard Apparatus, Holliston, MA). A parallel plate flow chamber apparatus (Glycotech, Rockville, MD) was affixed to the tissue culture plate and flow was adjusted to achieve a shear stress of 1.5 dyne/cm2. Six minutes after the initiation of flow, four randomly selected fields were videotaped for 1020 s under phase microscopy and subjected to computer-aided video analysis. NIH Image 1.62 with macros provided by K. Tangemann (Novartis, Vienna, Austria) was used for quantification of rolling and arrested cells as described (10, 25).
For flow assays on cultured HDMEC, cells were grown to confluence in
35-mm tissue culture dishes and stimulated with 10 ng/ml recombinant
human TNF-
for 45 h at 37°C. In some cases, JK cells were
incubated with mouse anti-human CD18 or CD49d mAb (10 µg/ml for
30 min) prior to initiation of the flow assay. Other cells were either
untreated or treated with pertussis toxin (PTX; 100 ng/ml;
Sigma-Aldrich) for 1.5 h at 37°C. All cells were labeled with
calcein-AM (1 uM for 20 min at 37°C). After washing with PBS, cells
were resuspended in cRPMI at 0.3 x 106 cells/ml
and then allowed to flow over recombinant human
TNF-stimulatedHDMEC at a shear stress of 1.5 dynes/cm2.
Five minutes after the initiation of flow, images were captured under
fluorescent illumination (excitation 485 nm, emission 515 nm) with an
exposure time of 2 s. Under these conditions, only cells that had
firmly arrested on the endothelial monolayers would generate a
single-cell image. Rolling cells appeared as streaks because of
movement during the long exposure time as previously described
(10). Statistical analyses were performed with Microsoft
Excel using two-sided Student t tests.
Confocal microscopy
JKFT7 cells expressing CCR6-EGFP were allowed to flow over plastic plates coated with E-selectin/Ig, ICAM-1, and CCL20 as described above. Washing was then carried out by pumping cRPMI over the attached cells for an additional 5 min at 1.5 dynes/cm2. The attached cells were stained with 5 µg/ml unlabeled mouse anti-human integrin chain mAb on ice for 30 min. After carefully washing twice with PBS/0.1% BSA, the cells were fixed with Cytofix buffer (BD PharMingen, San Diego, CA) on ice for 30 min followed by washing with BD PharMingen staining buffer containing FBS (BD PharMingen). Cells were then sequentially labeled with biotin-labeled goat anti-mouse IgG (Caltag Laboratories, San Francisco, CA) for 20 min on ice and streptavidin-Cy3. The cell surface distribution of CCR6-EGFP and integrins were then analyzed with a Nikon PCM2000 confocal microscope (Nikon, Melville, NY).
Isolated mTC were also allowed to flow over TNF-
-activated HDMEC as
previously described (10). After 5 min of flow followed by
washing, attached cells were fixed with Cytofix and stained with
anti-CCR6 mAb (R&D Systems), a biotin-labeled secondary Ab, and
streptavidin-Cy3.
Quantitative real-time RT-PCR
RNA extraction and reverse transcription were performed as
described (26). Real-time quantitative PCR (PerkinElmer
ABI7700; PerkinElmer, Wellesley, MA) was performed with
duplicate samples using SybrGreendye and human primer pairs
(see Table I
) derived from Genbank sequences. All primer
pairs were designed to give products between 65 and 75 bp in length,
gave rise to single band products, and had similar efficiencies of
exponential amplification. Cycle threshold numbers (Ct) were derived
from the exponential phase of PCR amplification.
|
| Results |
|---|
|
|
|---|
For effective rolling and arrest of mTC to activated HDMEC under
shear stress conditions, we have found that human mTC must express
E-selectin ligand as detected by mAb recognizing the CLA marker. In
conjunction with this, E-selectin must be expressed by the activated
HDMEC. As shown in Fig. 1
A,
total mTC depleted of CLA+ cells showed
70% less arrest
compared to total mTC. Likewise, treatment of the endothelial cells
with a function-blocking anti-E-selectin mAb markedly reduced mTC
arrest. Thus, in contrast to large vessel endothelial cells (e.g.,
HUVEC), which have been reported to support the rolling of
CD4+ T cells via VCAM-1 and P-selectin and are not
dependent on E-selectin expression (27), E-selectin
appeared to be critical for rolling and, indirectly, arrest of mTC on
HDMEC. This important difference may be due in part to differential
regulation of E-selectin and VCAM-1 expression on HUVEC vs HDMEC
(28, 29).
|
Construction and characterization of CCR6-EGFP fusion protein
We next constructed a chimeric CCR6 in which CCR6 was fused at its
C-terminal end to EGFP (see Materials and Methods) such that
the resulting receptor could be visualized by fluorescence microscopy
or flow cytometry. Similar chemokine receptor-EGFP chimeric receptors
appear to be fully functional and comparable to the wild-type receptor
(30). After transducing JKFT7 cells with this CCR6-EGFP
construct followed by initial sorting and selection, 95% of the
resulting transduced cells (JKFT7-CCR6) were EGFP, CCR6, and CXCR4
positive (Fig. 2
A). However,
the expression of CCR6-EGFP tended to decrease slightly over time.
Thus, all experiments were performed on cells within 3 wk of
transduction and selection when EGFP expression was >70% positive.
The CCR6-EGFP fusion protein was evenly distributed on the cell
membrane in resting cells (Fig. 2
B), whereas cells
transduced with EGFP alone expressed EGFP uniformly in cytoplasm (data
not shown). By flow cytometric analysis, JKFT7-CCR6 cells did not
express
7 integrin, but were uniformly positive for CD18
(
2), CD11a (
L), CD49d (
4),
and CD29 (
1) integrin chains (Fig. 2
C).
|
|
Because the chemotactic response of lymphocytes to a particular
chemokine does not always correlate with the ability of that chemokine
to induce arrest under shear stress conditions (8), we
introduced JKFT7-CCR6 and control JKFT7-EGFP cells into a flow chamber
coated with recombinant E-selectin, ICAM-1, and various chemokines. As
shown in Fig. 4
, control JKFT7-EGFP cells
arrested poorly on CCL20-coated plates, but arrested well on
CXCL12-coated plates. However, JKFT7-CCR6 cells arrested in the
presence of CCL20 to the same level observed with CXCL12. The weak
stimulation in adherence in the presence of CCL20 for both cell lines
was most likely nonspecific, because adherence in the presence of CCL17
was also marginally increased to the same degree. At shear stresses
higher than 1.5 dyn/cm2, e.g. 2.0, 2.5, and 3.0
dynes/cm2, the number of rolling and arrested cells
decreased; yet at all shear stresses tested, there were greater numbers
of arrested JKFT7-CCR6 than control cells (data not shown). Thus,
expression of CCR6 stimulated the ability to JK T cells to arrest on
recombinant adhesion molecules coated to plastic in the presence of
CCL20.
|
The arrest of mTC to activated HDMEC under shear stress conditions
can be blocked by
70% by saturation of CCR6 with CCL20, by PTX
treatment, or by depleting total mTC of the CCR6+ subset of
mTC (10). These results suggested that CCR6 was necessary
for arrest of a subset of mTC to activated HDMEC under in vitro
conditions, but we could not demonstrate that, among chemokine
receptors, CCR6 was sufficient for effective arrest to occur.
Therefore, we introduced JKFT7-CCR6 and control JKFT7-EGFP cells at a
physiologic flow rate into a parallel plate flow chamber containing
activated HDMEC. Interactions in the absence of TNF-
pretreatment
were negligible, and arrested cells were rarely observed (data not
shown). The two cell lines were labeled with fluorescent dye, calcein,
which allowed us to quantify arrested and rolling cells. After exposure
of HDMEC monolayers to TNF-
, calcein-labeled cells were observed to
transiently bind, roll, and arrest. In the case of EGFP-transduced
JKFT7 cells, a low number of arrested cells were observed at baseline
(Fig. 5
). This likely indicated the
existence of a CCR6-independent cell arrest pathway in JKFT7 cells.
CCR6-EGFP expressed in JKFT7 cells significantly enhanced cell arrest
on activated HDMEC by 2- to 3-fold (Fig. 5
). Interestingly, the
enhanced arrest in JKFT7-CCR6 cells was abolished by treating cells
with anti-CD18 mAb which targets
2 integrin, but not
by anti-CD49d (
4 integrin) mAb. PTX, which blocks
the Gi-protein-coupled signal transduction pathway, also
completely suppressed the enhanced arrest observed with the JKFT7-CCR6
cells. Decreased rolling cells were also observed in both
CCR6+ and CCR6- JK cells that had been treated
with PTX and anti-CD18 mAb, a finding which might be explained by a
requirement of functional
2 integrin/ICAM-1 adhesion for
optimal selectin-mediated rolling (31). Thus, the
expression of CCR6 in JKFT7 cells effectively stimulates arrest that is
PTX-sensitive and
2, but not
4,
integrin-dependent.
|
2
integrin in JKFT7-CCR6 cells after exposure to immobilized CCL20
Previous reports have suggested that chemokine receptors on
lymphocytes redistribute to the leading edge of polarized migrating
cells in response to a soluble, chemotactic ligand (12)
and that ligation of chemokine receptors induces the lateral movement
of
2 integrins on lymphocytes (11).
Therefore, we hypothesized that chemokine receptors may colocalize with
integrins. To test this hypothesis, we took advantage of the fact that
EGFP was fused to the C-terminal end of CCR6 in our JKFT7-CCR6 cells,
allowing us to follow CCR6 distribution both in real time and after
fixation. After JKFT7-CCR6 cells arrested on recombinant substrates and
CCL20 as in Fig. 4
, we stained the arrested cells in separate
plates with mAb to CD18 (Fig. 6
, AC), CD11a (Fig, 6,
DF), and CD49d (Fig. 6
, HJ). With CD18 and CD11a, there was clear
colocalization of CCR6 (green) with CD18 and CD11a (red). The overlap
of red and green signals can be seen in Fig. 6
, A and
D as a yellowish hue. CD49d did not appear to strictly
colocalize with CCR6, although we did observe individual cells (Fig. 6
, HJ, cell on right) that hinted at possible
colocalization. Repeated experiments in which VCAM-1/Ig (in addition to
ICAM-1 and E-selectin/Ig) was coated onto tissue culture plates
revealed that clearer association of CD49d with CCR6, suggesting that a
suitable
4
1 ligand was required for
maximal colocalization of the
4 integrin with CCR6 (data
not shown).
|
40%
express CCR6) to arrest on TNF-
-activated HDMEC monolayers under
flow conditions as previously described (10), and then
stained the cells with an anti-CCR6 mAb (red) (Fig. 6
2 integrins (and to a
lesser extent
4 integrin) appeared to colocalize with
CCR6 during this process. | Discussion |
|---|
|
|
|---|
Our data add additional support for the role of CCR6 in the recruitment of CCR6-expressing subsets of mTC to sites of inflammation. We demonstrated that the presence of CCR6 enhances the adhesion of our model T cells to both recombinant substrates and activated microvascular endothelial cells. The lack of CCRs such as CCR1CCR10 on the starting JK cells provided a system by which we could test the efficacy of CCR6 alone in mediating arrest. Although JK cells expressed CXCR4, activated HDMEC in our previous study produced little or not CXCL12 mRNA by comparison with CCL20 (10). Thus, this receptor is unlikely to play a role in JK attachment to activated HDMEC in our in vitro flow model.
The use of a CCR6-EGFP fusion protein allowed us to determine the
distribution of CCR6 in relationship to that of
2
integrins, which have been reported to cluster following chemokine
receptor-mediated signaling (11). Surprisingly, we
observed clear colocalization of CD18 and CD11a integrin chains (i.e.,
LFA-1) with CCR6 (Fig. 6
, AF). To our
knowledge, this association has not previously been reported in the
literature, although chemokines have been reported to induce the
redistribution of ICAM-1, CD44, and CD43 to lymphocyte uropods
(32) and of LFA-1 (11). We caution that
colocalization does not necessarily suggest physical
coassociation of CCR6 and
2 integrin.
Immunoprecipitation studies to determine this await suitable Ab
reagents. Although not formally addressed, it was possible that the
changes in lateral mobility of
2 integrin observed by
Constantin et al. (11) may have coincided with the spatial
redistribution of chemokine receptors.
The
4 integrin forms one chain of CD49dCD29
(
4
1 or very late Ag-4), an
integrin capable of mediating both rolling (33) and arrest
(34) of lymphocytes under flow conditions. Since
7 integrin was not expressed by our JKFT7-CCR6 cells
(Fig. 2
), we presume that most of the
4 integrin on
these cells was associated with
1 integrin to form very
late Ag-4. However, adhesion of JKFT7-CCR6 to activated HDMEC was not
inhibited by anti-
4 mAb. This may have been due to
differences in the kinetics and expression of VCAM-1 on HDMEC vs HUVEC
(28, 29). Furthermore,
4 integrin did not
appear to colocalize with CCR6 (Fig. 6
, HJ) to
the same extent as did CD11a and CD18 (Fig. 6
, AF) on ICAM-1 in the flow chamber, although
colocalization of
4 integrin was clearly enhanced when a
recognized
4
1 ligand, VCAM-1/Ig, was
coimmobilized on the surface. This suggests that clustering of
integrins is at least partially dependent on the presence of a suitable
integrin ligand. Although differential regulation of
1
vs
2 integrin function in T cells by chemokines is
possible under some conditions (35, 36), our experiments
demonstrated similar clustering of
1 and
2 integrins on the cell surface in response to CCL20 as
long as both VCAM-1 and ICAM-1, respectively, were immobilized on the
plate.
In summary, we provide additional data that support an important role
for CCR6 in the arrest of a subset of mTC to activated endothelium.
Secondly, we demonstrate that CCR6 clearly colocalizes with CD11aCD18
(LFA-1) integrin. The clustering of the CCR6 appeared to be a specific
response to CCL20 since CXCR4, while similarly showing redistribution
in response to plate-bound CXCL12 (Fig. 6
O), did not
redistribute on the membrane when CCL20 was used to induce arrest (Fig. 6
, MN). Although we could not follow integrin
clustering (i.e., avidity changes) in real time, colocalization of
2 and
1 integrins with CCR6 (before,
during, or after CCR6 redistribution) may provide a basis for
increasing the strength of the interaction between T cells and relevant
physiological targets such as activated endothelial cells. As suggested
by the work of Constantin et al. (11), increased avidity
of LFA-1 may be of particular importance at the early stages of
inflammation when ICAM-1 expression is low. Since CCR6 is expressed by
both CLA+ (so-called skin-homing T cells) as well as by
4
7+ mTC (so-called gut-homing
T cells), CCR6 is unlikely by itself to lend absolute homing
specificity to one organ vs another. However, because CCR6 is both
necessary and sufficient for T cell homing in our in vitro system,
pharmacologic inhibitors of CCR6 may be of potential value in
preventing undesirable T cell influx in multiple organs.
| Footnotes |
|---|
2 Abbreviations used in this paper: mTC, memory T cell; FT7,
(1,3)fucosyltransferase VII; EGFP, enhanced green fluorescent protein; PTX, pertussis toxin; HDMEC, human dermal microvascular endothelial cell; CCL, CC chemokine ligand; CLA, cutaneous lymphocyte-associated Ag; CXCL, CXC chemokine ligand; JK, Jurkat; Ct, cycle threshold number. ![]()
Received for publication August 1, 2001. Accepted for publication July 2, 2002.
| References |
|---|
|
|
|---|
(1,3)fucosyltransferase Fuc-TVII controls leukocyte trafficking through an essential role in L-, E-, and P-selectin ligand biosynthesis. Cell 86:643.[Medline]
2 integrin affinity and mobility changes: differential regulation and roles in lymphocyte arrest under flow. Immunity 13:759.[Medline]
. J. Immunol. 162:186.
/CCL20 and CC chemokine receptor 6 in psoriasis. J. Immunol. 164:6621.
-chemokine. Blood 89:3315.
1 integrin. J. Leukocyte Biol. 59:872.[Abstract]
-activated vascular endothelium under flow. J. Exp. Med. 181:1179.
and interleukin-1
in dermal microvascular endothelial cells. Blood 87:211.
-activated vascular endothelium under flow. J. Exp. Med. 181:1179.
1 integrin-dependent adhesion in human Th2 T lymphocytes. J. Immunol. 164:3292.
2,
3, and
7 integrin activity. J. Immunol. 160:5622.This article has been cited by other articles:
![]() |
A. Ito, T. Suganami, A. Yamauchi, M. Degawa-Yamauchi, M. Tanaka, R. Kouyama, Y. Kobayashi, N. Nitta, K. Yasuda, Y. Hirata, et al. Role of CC Chemokine Receptor 2 in Bone Marrow Cells in the Recruitment of Macrophages into Obese Adipose Tissue J. Biol. Chem., December 19, 2008; 283(51): 35715 - 35723. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sugaya, L. Fang, A. R. Cardones, T. Kakinuma, S. H. Jaber, A. Blauvelt, and S. T. Hwang Oncostatin M Enhances CCL21 Expression by Microvascular Endothelial Cells and Increases the Efficiency of Dendritic Cell Trafficking to Lymph Nodes J. Immunol., December 1, 2006; 177(11): 7665 - 7672. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Cardones, T. Murakami, and S. T. Hwang CXCR4 Enhances Adhesion of B16 Tumor Cells to Endothelial Cells in Vitro and in Vivo via {beta}1 Integrin Cancer Res., October 15, 2003; 63(20): 6751 - 6757. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |